Event-Driven Stocks

Arbutus Biopharma Corp

ABUSNasdaq

Healthcare · Pharmaceutical Preparations · A1 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 3 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$14.1M$6.2M$18.1M$39.0M$11.0M$6.9M
Operating income−$38.2M−$76.3M−$78.1M−$65.5M−$73.5M−$57.8M
Net income−$33.5M−$69.9M−$72.8M−$69.5M−$76.2M−$63.7M
Total assets$94.6M$131.7M$144.4M$195.4M$204.5M$137.1M
Total liabilities$18.0M$34.3M$38.4M$58.6M$35.0M$35.1M
Equity$76.6M$97.4M$106.0M$136.9M$169.4M$102.0M
EPS (diluted)$-0.17$-0.38$-0.44$-0.46$-0.83$-1.00
Shares out.191.5M179.5M162.6M148.6M95.6M68.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−271.0%
Net margin
−237.9%
Return on equity
−43.7%
Return on assets
−35.4%
Return on capital (ROCE)
−43.1%
Liabilities / assets
19.1%
Debt / equity
0.24×
Book value / share
$0.40
Revenue growth (YoY)
128.2%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-39.67distress
Accruals / assets
6.5%moderate
Piotroski F-Score
5/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
55
/ 100
Profitability 0Growth 100Catalyst 67Earnings quality 33Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 3 warning● 2 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202616.4M17.1-7.4%
Apr 30, 202617.7M7.2-0.3%
Apr 15, 202617.8M11.4+10.1%
Mar 31, 202616.2M7.0-1.4%
Mar 13, 202616.4M4.2+11.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)